Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Fig. 1

Gantenerumab development and key scientific advancements in AD. Key events and decisions that informed the gantenerumab clinical development program, ultimately leading to the GRADUATE I and II studies—2 ongoing phase 3, global, randomized, parallel-group, placebo-controlled clinical trials evaluating the efficacy and safety of subcutaneous gantenerumab in early AD (i.e., mild cognitive impairment due to AD to mild AD dementia), the launch of secondary prevention trials designed to remove amyloid plaques before symptom onset, and a primary prevention trial designed to prevent formation of amyloid plaques

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193